pyrroles has been researched along with Leukocyte Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM | 1 |
| Chamberlain, JM; Daiss, JL; Dewhurst, S; Gelbard, HA; Goodfellow, V; Kim, M; Lebron, L; Polesskaya, O; Wong, C | 1 |
| Balagué, C; Godessart, N; Pont, M; Prats, N | 1 |
3 other study(ies) available for pyrroles and Leukocyte Disorders
| Article | Year |
|---|---|
Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alanine Transaminase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Aspartate Aminotransferases; Atorvastatin; Body Weight; Bone Density Conservation Agents; Dental Cementum; Gingiva; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Parenteral; Injections, Subcutaneous; Isoenzymes; Leukocyte Disorders; Leukocytes; Leukocytosis; Male; Monocytes; Neutrophils; Peroxidase; Pyrroles; Rats, Wistar; Root Resorption; Tartrate-Resistant Acid Phosphatase | 2014 |
MLK3 regulates fMLP-stimulated neutrophil motility.
Topics: Animals; Cell Migration Inhibition; Cell Survival; Cells, Cultured; Chemotactic Factors; Immune System Diseases; Leukocyte Disorders; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase Kinase Kinase 11; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Protein Kinase Inhibitors; Pyridines; Pyrroles | 2014 |
Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Crotonates; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Gastrointestinal Tract; Half-Life; Hydroxybutyrates; Hypercholesterolemia; Immunosuppressive Agents; Janus Kinases; Joints; Leukocyte Disorders; Male; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Splenomegaly; Toluidines; Weight Loss | 2012 |